Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Pain|April 21, 2025
Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318Lisa M Broad, Jeffrey G Suico, P Kellie Turner, et al.Experimental Physiology|September 1, 2023
The atypical 'hippocampal' glutamate receptor coupled to phospholipase D that controls stretch-sensitivity in primary mechanosensory nerve endings is homomeric purely metabotropic GluK2Karen J Thompson, Sonia Watson, Chiara Zanato, et al.Neuropharmacology|January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonistJeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2015
123I-iododexetimide preferentially binds to the muscarinic receptor subtype M1 in vivoGeor Bakker, Wilhelmina A Vingerhoets, Jan-Peter van Wieringen, et al.The Journal of Clinical Investigation|December 20, 2016
M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory lossSophie J Bradley, Julie-Myrtille Bourgognon, Helen E Sanger, et al.Nature Chemical Biology|February 22, 2020
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugsSophie J Bradley, Colin Molloy, Paulina Valuskova, et al.Journal of Medicinal Chemistry|January 20, 2018
Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor AgonistJames A Monn, Steven S Henry, Steven M Massey, et al.Journal of Medicinal Chemistry|January 21, 2015
Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structuresJames A Monn, Lourdes Prieto, Lorena Taboada, et al.Cell|November 25, 2021
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's diseaseAlastair J H Brown, Sophie J Bradley, Fiona H Marshall, et al.Pageof 4